Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298027 | 0.86 | MMP13 (0.81) | MMP13PDPK1 | |
| SCHEMBL5697074 | 0.78 | MMP13 (1.00) | MMP13PDPK1 | |
| SCHEMBL6427533 | 0.78 | MMP13 (0.82) | MMP13 | |
| SCHEMBL5696853 | 0.77 | MMP13 (0.73) | MMP13PDPK1 | |
| SCHEMBL6302703 | 0.77 | MMP13 (0.84) | MMP13 | |
| SCHEMBL6297353 | 0.77 | MMP13 (1.00) | MMP13 | |
| SCHEMBL5696895 | 0.76 | MMP13 (1.00) | MMP13 | |
| SCHEMBL5697007 | 0.75 | MMP13 (1.00) | MMP13 | |
| SCHEMBL6296178 | 0.74 | MMP13 (0.82) | MMP13 | |
| SCHEMBL6302830 | 0.74 | MMP13 (0.82) | MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063673-A1 | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors | JOHNSON ADAM RICHARD (US) | 2004-04-01 | — | — | US | claimed |
| WO-2004014384-A2 | CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-20040063673-A1 | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors | JOHNSON ADAM RICHARD (US) | 2004-04-01 | — | — | US | disclosed |
| WO-2004014384-A2 | CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063673-A1 | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors | MMP13, MMP1, MMP11 | MMP13 1/4885PDPK1 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.